Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: sailor who wrote (2908)	12/1/1997 10:38:00 AM
From: g.w. barnard	Read Replies (1) \| Respond to of 23519

sailor, is this what you are talking about?? gw GREAT NECK, N.Y., Dec. 1 /PRNewswire/ -- Robert M. Cohen & Co. analyst Keith R. Bossey upgraded his rating on Vivus, Inc. (NASDAQ:VVUS) to a buy from speculative buy and maintained his six-month price target of $50.50 per share. The upgrade was based on Vivus' announcement that it gained regulatory approval to market its Muse impotence treatment in the United Kingdom. SOURCE Robert M. Cohen & Co.

To: sailor who wrote (2908)	12/1/1997 10:41:00 AM
From: Whipsaw	Respond to of 23519

Astra's approval release: biz.yahoo.com Astra gets UK approval for impotence drug STOCKHOLM, Dec 1 (Reuters) - Swedish drugs company Astra said on Monday it had received approval from Britain's Medicines Control Agency for its new impotence treatment product, MUSE. Astra said other European regulatory authorities are expected to follow the British decision in accordance with the European Union's mutual recognition procedure. ''The first launch in Europe is expected to take place in the beginning of 1998,'' Astra said in a statement. MUSE, which contains the active substance alprostadil, offers patients a new, user-friendly alternative for the effective treatment of erectile dysfunction. Astra said it has exclusive marketing and distribution rights to the product in Europe, Australia, New Zealand, South America and a number of other countries through an agreement with VIVUS Inc (Nasdaq:VVUS - news) in California. An estimated 70 percent of men aged over 65 experience some degree of impotence, the company said.